Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
- Details
- Category: Boehringer Ingelheim
![Boehringer Ingelheim Boehringer Ingelheim](/images/logo/boehringer-ingelheim.png)
FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
GSK completes acquisition of Sierra Oncology
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
More Pharma News ...
- GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries
- Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
- Boehringer Ingelheim signs option to acquire Trutino Biosciences
- Positive Phase 1 data from mRNA-based individualized neoantigen specific immunotherapy in patients with resected pancreatic cancer
- Pfizer to invest $120 million to produce COVID-19 oral treatment in the U.S.
- FDA approves RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for adults with moderate to severe rheumatoid arthritis
- Sandoz announces new global 'Act4Biosimilars' initiative